(NYSE: DNA) Ginkgo Bioworks Holdings's forecast annual revenue growth rate of 8.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.86%.
Ginkgo Bioworks Holdings's revenue in 2025 is $180,606,000.On average, 5 Wall Street analysts forecast DNA's revenue for 2025 to be $10,645,701,478, with the lowest DNA revenue forecast at $10,232,476,185, and the highest DNA revenue forecast at $11,216,461,341. On average, 5 Wall Street analysts forecast DNA's revenue for 2026 to be $11,420,650,379, with the lowest DNA revenue forecast at $9,787,743,977, and the highest DNA revenue forecast at $12,832,402,482.
In 2027, DNA is forecast to generate $14,791,284,262 in revenue, with the lowest revenue forecast at $14,352,005,175 and the highest revenue forecast at $15,377,191,680.